Look Who is Attending the 16th Annual Drug Delivery Partnerships!

We call our event Drug Delivery Partnerships for a reason. The networking and partnering opportunities found here every year are unmatched. That’s why companies keep coming back, and new ones join us every year.

In Las Vegas next week, from January 25-27, you will have the opportunity to network with hundreds of companies involved in drug delivery.  If you'd like to join these companies, register today and use code XP1778BLOG to receive 25% off the standard rate!

Here is a full list of all the companies attending: 

3M Pharmaceuticals * Abbott Laboratories * Accredo Health Incorporation* Activaero * Acura Pharmaceuticals * Aisling Capital * Alkermes Inc * Allergan Incorporation * Amcor Rigid Plastics * Amgen Incorporation * Aparna Biosciences Corporation * Aprecia Pharmaceuticals * Apricus Bio/NexMed USA * Aptalis Pharma Tech Incorporation * Aptar Pharma * Aradigm Corporation * Arecor * ARx LLC * ASLAN Pharmaceuticals * Astellas Pharma US Incorporation * AstraZeneca * Aveva Drug Delivery Systems Incorporation * Banner Pharmacaps Inc * Battelle Product Development Group * Bausch + Stroebel * Baxter Healthcare Corporation * Bayer Healthcare Pharmaceuticals Incorporation * BD Biosciences * Becton Dickinson & Company * Bespak * Biochemics Incorporation * Biocodex Incorporation * Boehringer Ingelheim * Bristol Myers Squibb * Buehler Motor Incorporation * Burrill & Company * Cambrex Corporation * Cambridge Consultants * Camurus AB * Carticept * Catalent Pharma Solutions * Chattem Incorporation * CIMA Labs * Columbia Analytical Services * Corium International Incorporation * Credit Agricole * Critical Pharmaceuticals * CSIRO * CSL Behring * Delpor Inc * Deutsche Bank * Dharma Therapeutics * Dow Corning Corporation * DSM Pharmaceuticals * Durect Corporation * Eisai Incorporation * Elcam Medical * Eli Lilly & Company * EMD Millipore Corp * Emergent Technologies Incorporation * Encompass Pharmaceutical Services Incorporation * Endo Pharmaceuticals Incorporation * Ethypharm USA * Evonik Degussa * Flamel Technologies * Flextronics Medical * Flugen * Galen Partners * Galenix Innovations * Gattefosse * Genentech Incorporationorporated * Genisphere Incorporation * GlaxoSmithKline Pharmaceuticals * Glide Pharma * Grunenthal * Haselmeier * Haynes & Boone Llp * Henkel Corporation * Hospira Incorporation * ICP Consulting * Inhalation * Insulet Corporation * Intec Pharma * Ipsen * Jaleva Pharmaceuticals * Janssen * Jazz Pharmaceuticals Incorporation * Johnson & Johnson * JRX Biotech * KAI Pharmaceuticals Incorporation * Kimberly Clark Corporation * Laboratoires Plasto Sante * Ligand Pharmaceuticals Incorporation * Lipocine Inc * Lux Research * Madeira Therapeutics * Mayne Pharma International * Medimetrics * MedImmune * Medpro Safety Products * Merck & Company Incorporation * Merial * Mikron * Millennium Pharmaceuticals Incorporation * MonoSol Rx * Morgan Lewis & Bockius LLP * NanoSmart Pharmaceuticals * NexMed Inc * Next Breath LLC * Nissen Consulting Group, LLC * Novaliq GmbH * Novartis * Noven Pharmaceuticals * Novo Nordisk * Novozymes Biopharma UK * OctoPlus * Ompi of America * Onconova Therapeutics Incorporation * OraPharma Incorporation * Owen Mumford * P/L Biomedical * Pacira Pharmaceuticals Incorporation * Pantec Solutions * Pantheon Pharmaceutical Service * Par Pharmaceutical Incorporation * Particle Sciences * PCCA * Pfizer * Pierre Fabre Medicament * PII * PL Developments * Plasto Technologies * PLD * PolyPeptide Laboratories Inc * PPI * Precision NanoSystems * Prime Therapeutics * PTM Consulting * Purdue Pharma LP * Q Chip *Ranbaxy Labs * Ratio Incorporation * Roth Capital Partners * Safety Syringes Incorporation * Sandoz Incorporation * SCD PharmaConsulting * SciDose LLC * Senfile Medical * SNBL Europe * Solubest * South University * SPI PHARMA * SteadyMed * Stevanato Group SPA * Supernus Pharmaceuticals Incorporation * Takeda Pharmaceuticals North America Incorporation * Tapemark Medical Products * Taris Biomedical * Teamtechnik Corporation * Technology Catalysts Corporation * Teicos Pharma Incorporation * Teikoku Seiyaku Company * Teva Pharmaceuticals * The Safepoint Trust * Thomas McNerney & Partners * TRL & MTS Business Development * Unigene Laboratories Incorporation * Unilife * University of Coimbra and LaserLeap Tech * University of Colorado * University of Copenhagen * University of Utah * Unomedical AS * UPM Pharmaceuticals * Upsher Smith Laboratories * Valeo Partners * Velocity Consulting * Vetter Pharma International USA * Washington Speakers Bureau * Watson Pharmaceuticals * West Pharmaceutical Services * Wilmington Pharmaceuticals * Wolfe Tory Med Inc * WR Grace * Z Cube SRL * Zogenix * Zydus Noveltech Incorporation

Share this article with your social network, just click below to share now!

Share |

DDP Complimentary Web Seminar: Drug Delivery: A Look Forward

Drug Delivery Partnerships 2012 keynote speaker G. Steven Burrill, CEO, Burrill Company will be joining us on December 20 at 1:30PM to kick-start your DDP Experience. join us for his complimentary web seminar, then join us in Las Vegas for his keynote presentation, "The Globalization of the Pharmaceutical and Biotechnology Industry: What Does it Mean for Your Bottom Line?"

About the web seminar:
The changing world of healthcare, not just driven by Washington and the healthcare reform dialogue, but by a confluence of technology changing everything from the way drugs/devices/diagnostics are discovered and developed to how they are delivered and paid for has revolutionized the industry. Never in the history of medicine have we seen such dramatic change! This seminar will discuss what these changes mean to the pharma and biotech industries.

What you will learn:
· What is happening now that’s causing dramatic change in the industry
· What is currently changing in the industry
· How the industry is adapting to this change
· What the future looks like

Presented by:  G. Steven Burrill, CEO, BURRILL & COMPANY
When: Tuesdsay, December 20, 2011, 1:30PM

Click here to register today! Mention Priority Code XP1778W1BLOG

Share this article with your social network, just click below to share now!

Share |

DDP Keynote Marc Koska talks to us about Drug Delivery’s role in Global Health

One of this year’s keynotes at the Drug Delivery Partnerships event is Marc Koska. He is the inventor of the first non-reusable syringe credited with saving over 10 million lives. In this DDP Exclusive Podcast, Mark Koska discusses how important the drug delivery community is for global health, as well as how Drug Delivery Partnerships facilitates not only forward-thinking business development, but also the betterment of health conditions worldwide.

Download the “Importance of Safe Drug Delivery in the Developing World” Podcast here.

During the podcast, Marc answers this question:
Has anyone from the pharmaceutical side of things ever reached out to you to partner directly? Or are they very much removed because, obviously, you are the technology as opposed to the drug?

His answer:

No, no one has ever reached out and it is a shame because we’ve always tried to pick up on that wave length. You know, if someone was selling, for instance, a Hepatitis vaccine, that they would want that safely delivered in the developing world (especially since it is where we focus most of our attention). And it seems a shame and it seems like a missed opportunity just simply because if a drug company/vaccine company wants to deliver a product with kudos, if you like, so that this one is as pure as it could possibly be, it seems like a great opportunity. But, we’ve never really picked that up and joined the two dots together. But I can understand why and that is because until you get the market reaching a tipping point, you can understand why people wouldn’t want to pioneer and put effort into putting another new item, another variable into the market. So, I can understand the reticence, but it seems like the time is really becoming now that we should be having those conversations.

As a reader of the The Drug Delivery Blog, you get a 25% discount off the standard rate when using code XP1778BLOG to register for Drug Delivery Partnerships 2012. The Event is taking place January 25-27, 2012, in Las Vegas. If you have any questions about the agenda or event, please contact Jennifer Pereira at jpereira@iirusa.com.

Share this article with your social network, just click below to share now!

Share |

The 2012 Drug Delivery Partnerships Brochure Is Ready for Download

Drug Delivery Partnerships is the meeting place to discover innovative products, anticipate and take advantage of trends in the partnering landscape and implement best practices to ensure your company stays ahead of the curve.  We invite you to download the exciting 2012 Drug Delivery Partnerships agenda!

By joining us January 25-27, 2012, in Las Vegas, you’ll have the opportunity to:

• Be a Part of the New Drug Delivery Partnerships Experience:
• 10+ Hours of Networking with 500+ Industry Professionals before, during and after the conference with our expanded partnering tool and at the conference in the DDP Hall
• 6 New Symposia, featuring Three Full Day Events including, “Manage Macromolecule Challenges to Deliver a Robust Biologic Product” and “Maximize the Potential of your Drug Delivery System through Drug Delivery Device Combination Products"
• 80 + Speakers including 40 New DDP speakers
• 40 + Technology Presenters with the latest drug delivery technology innovations

Click here to download the 2012 Drug Delivery Partnerships brochure today!

And, as a reader of the The Drug Delivery Blog, you get a 25% discount off the standard rate when using code XP1778BLOG! If you have any questions about the agenda or event, please contact Jennifer Pereira at jpereira@iirusa.com.

Share this article with your social network, just click below to share now!

Share |

Happy Holidays from Future of Biopharma

We're taking some time off from our coverage of biopharma to celebrate the season with our loved ones. We want to sincerely thank you for your readership, your comments and your participation. We look forward to returning to the world of Pharma in 2011!

Here are our top posts from 2010:
FDA approves first biosimilar
2010 DDP Awards: Technology Innovation Nominee: Topi-Click
How will healthcare reform affect Pharma?

We wish you Happy Holidays!

Share this article with your social network, just click below to share now!

Share |

Your invitation to attend the CRS Product Development Forum - Poorly Soluble Drugs

CRS Product Development Forum – Poorly Soluble Drugs

January 27-28, 2011
Doral Golf Resort & Spa
Miami, Florida U.S.A.

You are invited to attend an informative two-day program devoted exclusively to the topic of poorly soluble drugs; CRS Product Development Forum – Poorly Soluble Drugs. January 27-28, 2011, Doral Golf Resort & Spa, Miami, Florida.

Who should attend? People from all fields involved in the development of drugs including receptor targets; drug discovery; ADME; pre-formulation (and formulation); human physiology; and in-vitro, in-silico, and in-vivo models and clinical trials (including special populations).

Understanding the Challenges of Poorly Soluble Drugs
Poorly soluble compounds compose an increasingly large percentage of the NCEs being developed today. These substances have great potential, but they present many challenges to effective delivery, including decreased bioavailability and inter-patient variability. Compounding these issues, many of the existing paradigms for drug development do not apply to poorly soluble compounds.

Unlocking the Door to New Paradigms in Drug Delivery
In spite of these challenges, the potential of poorly soluble drugs is too great to be ignored. By developing new formulation strategies, better technologies for enhancing drug solubility, and more efficient methods of delivery, we can extend the life cycle of established low-solubility drugs, increase the number of poorly soluble drug candidates for development, and deliver highly effective and economically efficient treatments to the patient.

This two-day forum will expose those involved in the discrete parts of the process to state-of-the-art information in all areas. With greater understanding of the full spectrum of problems, we can unlock the door to new paradigms in the development and delivery of poorly soluble drugs, to the benefit of patients and the industry. Register now!

This year, the CRS Product Development Forum is co-located with the 15th Annual Drug Delivery Partnerships, January 26-28, 2011, also at Doral. Ask about registration discounts when registering for both meetings.

PROGRAM HIGHLIGHTS

Plenary Topics
Pros & Cons of BSC in Drug Discovery
Formulation Strategies for Delivering Poorly Soluble Actives
Formulation Strategies with Emphasis on Class 4 Compounds—Good Case Stories
Lipolysis Modeling and Food Effect

Session Topics
Human GI Physiology
In-Vivo Studies of Absorption of Poorly Soluble Actives
Solution/Semi-solid Formulation Approaches
In-Vitro Methodologies
Mid- to Late-State Development (Phase II and Beyond)

Click here to view the complete program with confirmed speakers.

CALL FOR PAPERS
October 29, 2010, is the last day to submit your abstract.

REGISTRATION
The registration deadline is January 4, 2011. Register today!

Share this article with your social network, just click below to share now!

Share |

Pfizer buying King Pharmaceuticals

Pfizer recently announced it's purchase of King Pharmaceuticals for #3.6 billion. Big pharma continues to buy small Pharma firms looking to acquire new products to their pipelines.

King's main products include, pain drugs, including painkillers designed to be resistant to abuse, and EpiPen, a pre-filled injection to treat allergic reactions. Pfizer has stated that they will cut $200 million in costs. News Observer has the full story.

Share this article with your social network, just click below to share now!

Share |

J&J receives FDA warning letter for unapproved med device products

CNN Money reports that the FDA has set Johnson and Johnson a warning letter for selling joint products have have yet to be approved. By selling these products, they are violating the Federal Food, Drug and Cosmetic Act. Upon receiving information from DePuy, the Johnson and Johnson subunit, it will then test products for market approval.

This blog is co-posted with The Drug Delivery Blog.

Share this article with your social network, just click below to share now!

Share |

Dr. Bill Maisel to direct Center of Devices and Radiological Health

According to MedCity News, Dr. Bill Maisel has been selected to function as the deputy director of science for the Center of Devices and Radiological Health (CDRH) and chair the Center Science Council (CSC). The latter will be responsible for issuing the recall of devices in addition to setting standards for their approval. This is stirring up some controversy in the medical device industry.

In a statement written for the House Energy and Commerce health subcommittee last year, Maisel wrote last year, he stated:“[I]t is critical that the safety and performance of medical devices be improved, that the frequency of medical device malfunctions and adverse events be reduced, and that patients and physicians be adequately informed about device clinical effectiveness and risks in a timely fashion. In short, FDA needs to improve its science-based device assessments and decision-making."

What effects do you think this will have on the medical device industry?

This blog is co-posted with the Drug Delivery Blog.

Share this article with your social network, just click below to share now!

Share |

What's next for the Pharma industry?

The Atlantic has a very interesting article looking at the future of the Pharma industry. With most of the patents set to expire at the end of next year, many companies are also facing pipelines with few products and low approval rates from the FDA. With the clinical trials being the most expensive parts medical development, in addition to the targets of new drugs being very small portions of the population, many drugs are shelved or are out of financial reach for many of the patients who need to use them.

Pharmaceutical companies are blamed for focusing on marketing at the expense of innovation: they allegedly kill promising compounds because of fears of small markets, then concentrate on “me too” drugs that aren’t really any better than their competition’s. Or they tweak existing drugs in ways that don’t necessarily make the drugs any more effective, but do give companies a new patented drug for which they can charge the Earth.

Read the article here.

Share this article with your social network, just click below to share now!

Share |

Drug Delivery Partnerships 2011 Industry Alert: Official Call For Presenters

From: Jennifer Sobrino, Conference Producer
Re: Call for Speakers & Presentations
Event Date: January 26-28, 2010
Event Venue: Doral Golf Resort & Spa, Miami, FL

SUBMIT YOUR PROPOSAL NOW!

The Institute for International Research (IIR) is currently seeking presenters for the 2011 15th Annual Drug Delivery Partnerships event. This 3-day event will take place January 26-28, 2011 in Miami, FL. We invite you to submit a proposal for a speaking opportunity directly to Jennifer Sobrino, by July 1, 2010. Please send to jsobrino@iirusa.com. Sessions will be 30-45 minutes including Q & A.

Submission Guidelines & Details

CUSTOMIZE YOUR CONFERENCE AGENDA!
We are currently recruiting drug delivery partnership executives who can share NEW DATA through detailed case studies related to leveraging the value of drug delivery to improve product pipelines, patient outcomes and boost innovation. This three day event will focus on current challenges the industry sees today and provide a forum for experts to come together and share knowledge and expertise.

Who will attend the leading industry conference on Drug Delivery Partnerships? Attendees will be both new and experienced drug delivery professionals in business development, technology, assessment & transactions, new product planning & development, R&D and more. We expect that the conference will attract between 400-500 attendees and are looking for novel approaches to handling drug delivery partnership issues including:

• Healthcare reform impact on reimbursement and innovation
• Drug delivery partnerships as a strategy for pipeline value creation
• Regulatory considerations
• Emergence of nanoparticulates as drug carriers
• Drug repurposing
• Innovation for OTC drugs
• Marketplace opportunities for biosimilars
• Regional preference for drug delivery methodologies in emerging markets
• Drug delivery focus in Latin America

MAKE SURE YOUR BIGGEST ISSUES ARE ADDRESSED!

Are your biggest concerns not addressed here? Contact Jennifer Sobrino at jsobrino@iirusa.com or 646.895.7310 to ensure that your pressing issue gets the attention it deserves!

Do you want to reach this audience?

We have a limited number of slots available for solution providers/consultants.
People who wish to become part of the program should contact, Sarah Scarry, Sponsorship Manager, at 646.895.7472 or sscarry@iirusa.com

Share this article with your social network, just click below to share now!

Share |

Q&A on Combination Products

I recently came across this white paper from Issac Medical Companies. It looks at various questions of combination products including:

-How do combination products work, and what advantages do they offer over other methods of drug delivery?
-How has the market arrived at the point where combination products are an important concept for the future of drug delivery?-How versatile are they in their applications?
-What scope is there to increase the range of applications in the future?

Read the white paper here.

Share this article with your social network, just click below to share now!

Share |

DDP Live: Pharmaceutical, Biotech and Drug Delivery Investment trends in the Current Economic Climate

Moderator: Les Funtleyder, Healthcare Strategist, Miller Tabak & Company and Author Healthcare Investing: Profiting from the New World of Pharma, Biotech, and Health Care Services
Elaine V. Jones, PhD, Executive Director, Venture Capital, Worldwide Business Development, Pfizer, inc.
Brett Zbar, MD, Partner, Aisling Capital
Art Pappas, Managing Director, Pappas Ventures
Joyce Lonergan, Former Partner, SR One, Chiron and President, The Pine Cone Company


How is the environment for deal making in drug delivery?
One panelist: Venture funding dried up. They looked to take care of their current portfolio, so the bar for current investment went up. Inside lead financing went on instead of looking to the outside. In 2010, companies holding their breath can’t do this forever.

From the venture side, they’re looking to add more cash. Most corporate venture capitalists look to have strategic vent to investing. Those who’ve done it for some time would like to make a return for investors. Funding proposals weren’t accepted warmly.

The investor that in 2009, it was interesting because: they closed their fund, and although they thought they’d be cautious, they had four deals last year. In certain situations they found it hard to say no to outstanding opportunities. They’ve got quite q few new deals, if the right kind of innovation is presented.

How are evaluations? Are stocks going down or are they stable?
-In 2009, most companies avoided financing. They sent that question into 2010 expecting things would improve.
-Looking at a private company, private and public valuations don’t adjust the same. If someone is going out to invest money, the valuation question should be approached appropriately. There is conversation, investors look at the fundamental case and how can business be built? Then valuation should be approached?
-The world has changed, things are worth half. One structural challenge is that venture capitalists don’t know what they’ll get rewarded for. It use to be positive Phase II and Phase III data, but it’s currently an unknown.

Other notes from the session:
*Always know how much capital is required to develop a profit.
*If you're going to a market with a product that already has a generic in the area, be sure to have the reason why your product will be able to surpass it in sales
*Do hard experiments at the beginning of your product testing, and make sure it's done effectively. Be able to construct clear answers for your investors as as opposed to meso-answers.

What are other areas that are currently interesting to venture capitalists?
-Biologics/biosimilars and delivery designs
-Value added biosimilars
-Delivery of vaccines
-Novel antibody scaffolds
-Pain treatments
-Syringes
-Ophthalmology

Share this article with your social network, just click below to share now!

Share |

DDP 2010: Understand How Payers View and Manage the Medical Pipeline to Improve Product Value Calculations

Moderator: Stanton R. Mehr, Publisher, The Medical Pipeline
Steven Avey, Vice President, Managed Care, PartnerSrx
C. Daniel Mullins, PhD, Professor, Pharmaceutical Health Services Research Department, University of Maryland School of Pharmacy
Scott Thompson, President, Pharmaceutical Practice, The Benfield Group
Raulo S. Frear, Pharm.D., Director, Pharmacy Services, The Regence Group

The Pharmaceutical Pipeline
There is an active pipeline development for compounds in the United States. Of the compounds in development, cancer is one of the top focuses. Are more compounds in the pipeline or are there slower approval rates by the FDA?

Product Value Categories of products on the market for Regence Rx: Effectiveness, safety, cost, persistency, convenience, me too product, no additional value. Over the last four years, the majority of the products have been classified as me too products or no additional value.

A few examples from the presentation:
Velaglucerase (Shire)
-What is it? Human cell line enzyme
-What does it do? Enzyme replacement therapy
-Likely indication: Type 1 Gaucher Disease

Data to date (8.3.2009)
-25 treatment native patients with Type 1 Gaucher disease
-2 doses administered
-Endpoints met (hemoglobin, platelet counts, spleen size)
-When do we expect to see it? 2Q-3Q, 2010
-What is the competition? Cerezyme (supply issues)

Fingolimond (Novartis)
-What is it? Immunosuppressant
-What does it do? Prevents egress of lymphocytes from lymph nodes
-Likely indication: Relapsing remitting multiple sclerosis

Share this article with your social network, just click below to share now!

Share |

2010 DDP Awards Winners

The 2010 DDP Awards were given out today. They were chosen by the voting of the 2010 Drug Delivery Partnerships Attendees. We would like to thank the nominees who joined us at DDP 2010 for the awards ceremony!


2010 DDP Award Winners:
Pipeline Value Creation: Halozyme Therapeutics
Partnering Excellence: Eurand
Technology Innovation: Elan Drug Technologies

Share this article with your social network, just click below to share now!

Share |

DDP 2010: Day 1 In Pictures

Take a moment to look back at DDP 2010 Day in in pictures:

Share this article with your social network, just click below to share now!

Share |

DDP 2010: Annual Wall Street Address: Retrospective View Over the Past Twelve Months

Annual WALL ST ADDRESS: Retrospective View Over the Past Twelve Months: Analyze the Economy’s Affects on Pharma and Drug Delivery and Prepare with an Outlook for the Future

David Steinberg, Managing Director, Equity Research, Specialty Pharmaceuticals and Drug Delivery
Deutsche Bank


The last two years has been interesting and stressful. Things are improving, but it is not clear or not if we are out of the recession. The year is looking up. As for healthcare, in 2008, pricing environment was reasonable and robust, international Rx growth was accelerating. In those stocks, smaller and risky companies weren’t doing well.

Why were healthcare stocks failing to perform?
-Investors were in trouble.
-Credit markets effectively shut down
-Equity financing was virtually non-existent
-There was a torrent of mutual funds and hedge fund redemption
-Smaller companies bore the brunt of the carnage

In 2008 there were 0 IPOs, in 2009, there were only two. Many companies no longer had to accept financing. Over 180 companies had less than one year’s cash. Now we were looking at a situation where hundreds of companies might go bankrupt.

Rabid Consolidation is a key theme in Pharma sector. There is an unprecedented amount of activity. There were 27 mergers in 2009, 4 were drug delivery companies.

Why?
-The bigger the company is the more likely they’re not going to have a great product pipeline.
-It’s a great exit strategy for private companies.
-Purchases of closely held companies to provide liquidity to a concentrated shareholder base

Who are the buyers? Usually we see branded specialty companies, generic companies, big Pharma, and private equity.

Who are the sellers?
-Profitable companies that have competitive/sustainability/critical mass issues
-Developmental state companies with attractive late-state pipelines that require major funding to market new products/receive FDA approval for both
-Special situations – attractive product partnership economics
-The “sweet spot” – profitable companies with market values between $750 mil and $5 billion

Stock Performance –
Acusphere, Aradigm, Neopharm, Middlebrook, and many others have had very poor stock performance over the past five years.

Optimized business model (CR model, etc) – stock performance has been very high. Shire, Kos, Adams Respiratory and New River Pharma have done very well.

Live cycle extension products –
-Generic drug companies helped change the rules of the game
-Managed care has caught on the life cycle extension game

How do you outsmart generics? David advised to start with the product idea and work backwards. Also look at what your company’s product strategy is, in addition to creating an opportunity for settlement. They key is to stay ahead of generics.

Unapproved drugs? Changing FDA regulations There are numerous unapproved drugs on the market if a company does clinical trials on it FDA grants exclusivity to the company

Abbott Tricor example great life cycle strategy
Adams Mucinex example Adams pursued NDA on guaifennesin-CR FDA granted exclusivity
Naispan Kos examples Abbott acquired Kos for $3.7B in November 2006
Vyvanse New River example a single enantiomer product of adderal a long lifecycle replacement for short duration $1B ADHD Drug

Some of the key recent launched:
Vyvance – Shire
Intuniv-Shire
Lialda-Shire
Zenpep-Eurand

Favorite Specialty Pharma stocks in 2010
Large cap- Teva Pharma (Teva), Shire Shire (SHPGY)
Mid cap – Bivail (BVF)
Small Cap: MAP Pharma (MAPP), Eurand (EURX)

Modest but prolonged recession? Look at these factors for 2010:
-Financial
-Investor base
-Regulatory side
-Political side

In 2009, things were very dismal. Now, if a company is looking to borrow money, it is available. The healthcare plan still will be a great influence on how these things work. At the current moment, the stock market could go either way. Companies with strong management teams who are willing to take risks and borrow money, devise some business plans and come up with the right product, they’ll survive and be rewarded with acquisitions and high stock prices among other things.

Share this article with your social network, just click below to share now!

Share |

Altea and KAI Pharmaceuticals Enter into a Preclinical and Clinical Development Agreement for the Transdermal Delivery of Certain Novel KAI Peptides

ATLANTA, Ga., January 13, 2010. Altea Therapeutics Corporation (“Altea”) announced today that it has entered into a partnership with KAI Pharmaceuticals, Inc. (“KAI”), a drug discovery and development company, for the preclinical and clinical development of certain KAI proprietary peptides utilizing Altea’s proprietary PassPort® Transdermal Delivery System.

Under the terms of the agreement, Altea and KAI will examine the transdermal delivery of certain KAI proprietary compounds using Altea’s novel transdermal delivery technology, the PassPort System. Altea has also granted KAI an option to receive a worldwide technology license for the further development and commercialization of these novel transdermal products. Should KAI exercise the option, KAI will fund all product development, manufacturing and commercialization activities, and Altea may receive license payments, development and commercialization milestones and royalties on product sales from KAI.

“We are pleased to enter into this agreement with KAI Pharmaceuticals, said Dr. Eric Tomlinson, PhD, DSc, President and CEO of Altea Therapeutics. “The agreement further validates the broad application of the Altea Therapeutics novel transdermal patch technology for the transdermal delivery of water-soluble compounds. While we continue to apply our transdermal technology to currently approved drugs that previously were administered by needle injection or infusion, including water-soluble proteins, carbohydrates and small molecules, this new partnership allows us to apply our technology to the new peptide drugs being developed by KAI Pharmaceuticals.”


About Altea Therapeutics

Altea Therapeutics is a privately held clinical-stage pharmaceutical company with a proprietary platform technology broadly applicable to the bolus or sustained transdermal delivery of biological drugs (proteins and carbohydrates) that otherwise would be administered by needle injection or infusion. The Company's PassPort® Transdermal Delivery System also is uniquely suited for delivering highly water-soluble low molecular weight drugs that otherwise could not be delivered transdermally.

Altea Therapeutics has partnered with Amylin Pharmaceuticals, Inc. and Eli Lilly and Company to develop and commercialize a novel daily transdermal patch delivering sustained levels of exenatide (currently marketed as Byetta®). The Company also has a partnership with Hospira, Inc. to develop and commercialize a transdermal patch for delivering enoxaparin sodium (currently marketed as Lovenox®) utilizing the PassPort® Transdermal Delivery System.

Altea Therapeutics is also in clinical development of a Transdermal Basal Insulin Patch for diabetes and a Transdermal Fentanyl Citrate Patch for pain. Additional information about Altea Therapeutics may be found at www.alteatherapeutics.com.

About KAI Pharmaceuticals

KAI is a drug discovery and development company with novel clinical-stage programs in cardiovascular disease, renal complications and pain. KAI’s lead product candidate, KAI-9803, is currently in a Phase 2b study (PROTECTION AMI) designed to assess the effect of KAI-9803 on reducing myocardial injury in heart attack patients. KAI’s second clinical program, KAI-1678, is in Phase 2a studies for pain. KAI’s third program, KAI-4169, is for the treatment of secondary hyperparathyroidism (SHPT) in kidney disease patients and is in IND-enabling studies.

KAI is the leader in the selective modulation of intracellular protein:protein interactions and delivery of peptides into the cell. This approach has broad potential and has been validated clinically. The Company has applied its core expertise to discover highly potent and selective inhibitors and activators for protein kinase C (PKC) isozymes. KAI is based in South San Francisco, California, and can be found online at www.kaipharma.com.

KAI is a registered trademark of KAI Pharmaceuticals.


**************************************************


NOTE: Altea Therapeutics, PassPort, Medicines Made Better. are either registered trademarks or trademarks of Altea Therapeutics Corporation, in the USA and/or other countries. All other brand names, product names or trademarks belong to their respective holders.


The statements in this press release regarding the products of Altea Therapeutics in development, product development plans and projected financial results, are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the ability of Altea Therapeutics to both complete the design, development and manufacturing process development of its products, manufacture and commercialize its products, obtain product and manufacturing approvals from regulatory agencies, manage its growth and expenses, finance its activities and operations, as well as marketplace acceptance of its products.

Share this article with your social network, just click below to share now!

Share |

DDP 2010: Workshop Day

A Day in Pictures: Drug Delivery Partnerships 2010

Share this article with your social network, just click below to share now!

Share |

Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products

Over 45% of all new indication approvals granted by the FDA since 1998 belong to drugs that fall in the Genito-urinary system and Nervous system.

Optimizing Lifecycle Management, a best selling report explains the basics of drug lifecycle and investigates three goals in optimizing product potential- expanding the drug’s patent protected lifespan, accessing broader patient populations and launching line-extensions via FDCs.

The need to derive the maximum commercial mileage from all components of a drug company’s portfolio is clearly evident in an era of falling returns on investment and higher capital costs. This best selling report investigates three goals in optimizing product potential- expanding the drug’s patent protected lifespan, accessing broader patient populations and launching line-extensions via fixed dose combinations.

The key success factors in each of these pursuits have been clearly identified, emerging trends have been presented and the underlying concepts have been explained to provide a clear understanding of current industry dynamics. Case studies on popular products have been used to illustrate these concepts in the real world. An in-depth analysis of drug approval data provides context for the issues discussed. This information is juxtaposed with historic sales data to explore the correlation between the strategies employed and revenue potential.

Gain an understanding of legal provision for patent protection and data exclusivity and understand their role in the context of product lifecycle management with this report from Business Insights, market leaders in strategic business information. Click here for more information on this title.

Share this article with your social network, just click below to share now!

Share |